EnGeneIC logo

News

November 11, 2015

EnGeneIC Ltd. to Present at the Stifel 2015 Healthcare Conference
October 15, 2015

EnGeneIC Ltd. to Present at The 14th Annual BIO Investor Forum
September 16, 2015

EnGeneIC Ltd. to Initiate U.S. Phase 1 Clinical Study Using Targeted EDV™ Nanocells to Treat Advanced Glioma Patients
August 19, 2015

EnGeneIC Initiates Phase 1 Tailored-EDV Clinical Study in Solid Tumors
August 6, 2015

Indian Link – In-gene-ious!
June 23, 2015

EnGeneIC Recognized as One of the Most Innovative Organizations in Australia at the 2015 Thomson Reuters Australian Citation & Innovation Awards
June 22, 2015

Sky News – Nanotech trial early success
June 15, 2015

EnGeneIC and Asbestos Diseases Research Institute Announce Encouraging Results from MesomiR-1 Phase 1 Trial in Late Stage Mesothelioma patients
April 16, 2015

Globe Newswire – Foundation for Sarcoidosis Research Announces First New York Fundraiser With Support of EnGeneIC
February 4, 2015

EnGeneIC to Present at BIO CEO & Investor Conference 2015
January 6, 2015

EnGeneIC Completes $10 Million Series B Financing Led by U.S. Institutional Investor
November 10, 2014

EnGeneIC and Asbestos Diseases Research Institute Initiate MesomiR-1 Phase 1 Trial in Patients with Late Stage Mesothelioma
September 15, 2014

EnGeneIC Named a Recipient of the Cancer Institute NSW Premier’s Award for Excellence in Translational Cancer Research
August 11, 2014

EnGeneIC Receives Patent from the USPTO for EDV™ Nanocell Technology
June 24, 2014

EnGeneIC Unveils Clinical Development Strategy for EDV™ Nanocell Technology
November 8, 2012

European CanCer Organisation – First trial in humans of “minicells”: a completely new way of delivering anti-cancer drugs